September 18, 2018 Bio/Pharma/CRO Clinical Research/Diagn. PR/Corporate

Reminder: Invitation to Roche's Virtual Pipeline Event: Key data for Roche's lung cancer portfolio to be presented at the 2018 IASLC World Conference on Lung Cancer

Basel, 18 September 2018 Reminder: Invitation to Roche’s Virtual Pipeline Event: Key data for Roche’s lung cancer portfolio to be presented at the 2018 IASLC World Conference on Lung Cancer Agenda Roche lung cancer portfolio key data IMpower133: Primary PFS, OS, and Safety in a Ph1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in... Read more

September 18, 2018 Clinical Research/Diagn.

Roche’s NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases

Basel, 18 September 2018 Roche’s NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases Roche launches an app ecosystem with the first two clinical decision support apps The apps query globally-renowned resources based on real-world data Patient-specific results lead to more personalised treatment decisions by oncology care teams Roche (SIX:... Read more

September 16, 2018 Clinical Research/Diagn. Liq. Handling & Robotics

QIAGEN and DiaSorin launch automated testing for latent TB infection with QuantiFERON-TB Gold Plus technology on widely used LIAISON platforms 

Hilden, Germany, and Saluggia, Italy, September 17, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE Italy Mid Cap: DIA) today announced the introduction of an automated, CE-marked workflow for QIAGEN’s QuantiFERON-TB Gold Plus Blood Collection Tubes (QFT-Plus BCT) and a novel DiaSorin LIAISON Test on widely used immunodiagnostic instruments from... Read more

September 16, 2018 Clinical Research/Diagn. Liq. Handling & Robotics M&A, Partnerships

QIAGEN and NeuMoDx announce strategic partnership to offer next-generation systems for fully integrated molecular diagnostic testing

Hilden, Germany, and Ann Arbor, Michigan, September 17, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and NeuMoDx Molecular, Inc. today announced a strategic partnership to commercialize two new fully integrated systems for automation of PCR (polymerase chain reaction) testing. These next-generation systems are specifically designed to help clinical molecular diagnostic laboratories process... Read more

September 14, 2018 Clinical Research/Diagn. Lab Top-10 Molecular Spectroscopy Product Launch

Bruker Introduces New High Performance Preclinical PET/CT Si78 System

SEATTLE, Sept. 14, 2018 /PRNewswire/ — Bruker today announced the introduction of the new preclinical PET/CT Si78 scanner for whole-body molecular imaging at the World Molecular Imaging Congress (www.wmis.org/2018-wmic). It combines Bruker’s novel PET and outstanding micro-CT technologies in a single scanner operated by the multi-modality imaging software platform ParaVision™ 360. The PET/CT Si78 is addressing... Read more

September 14, 2018 Clinical Research/Diagn. Microscopy Product Launch

Bruker Introduces New High Performance Preclinical PET/CT Si78 System

SEATTLE, Sept. 14, 2018 /PRNewswire/ — Bruker today announced the introduction of the new preclinical PET/CT Si78 scanner for whole-body molecular imaging at the World Molecular Imaging Congress (www.wmis.org/2018-wmic). It combines Bruker’s novel PET and outstanding micro-CT technologies in a single scanner operated by the multi-modality imaging software platform ParaVision™ 360. The PET/CT Si78 is addressing... Read more

September 12, 2018 Clinical Research/Diagn. Licensing, IP, and Legal

Quanterix Announces Termination of License Agreement With Biomérieux

Secures and Consolidates Unrestricted Rights for Simoa Technology in Diagnostics Market LEXINGTON, Mass.–(BUSINESS WIRE)–Sep. 12, 2018– Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the consolidation of its licensing position and reestablishment of control of its intellectual property in the in vitro diagnostics (IVD) field. The termination... Read more

September 11, 2018 Clinical Research/Diagn. Informatics & Software Life Science Tools M&A, Partnerships

Seven Bridges & e-NIOS Partnership to Break the Biomarker Bottleneck

September 11, 2018 Cambridge, Mass. and Athens, Greece., Sept 11, 2018. Seven Bridges, the leading biomedical data platform and analytics company, and e-NIOS, a biological knowledge discovery start-up, announced a strategic partnership towards data-driven discovery of biomarker signatures. Derivation of robust biomarkers from next generation sequencing and multi-omic data is currently a major bottleneck in precision medicine... Read more

September 10, 2018 Clinical Research/Diagn. Informatics & Software Life Science Tools M&A, Partnerships Product Launch

Seven Bridges announces the launch of largest pediatric data resource as a member of the Gabriella Miller Kids First Data Resource Center

September 10, 2018 Cambridge, Mass. Sept 10, 2018. Seven Bridges, the leading biomedical data platform and analytics company, today announced the launch of the new Kids First Data Resource Portal with the Gabriella Miller Kids First Data Resource Center (DRC) at the Center for Data Driven Discovery in Biomedicine (D3b) at Children’s Hospital of Philadelphia. The Gabriella Miller Kids First Data Resource... Read more

September 4, 2018 Clinical Research/Diagn. Product Launch

Pushing the Boundaries in Automation – First Glimpse of Next-Generation Solution for Endotoxin Detection at PDA 2018

Walkersville, MD (USA)/Basel (CH), 3 September 2018 – Lonza will reveal its next-generation endotoxin automation solution, PyroTec™ Pro Robotic Solution at the Parenteral Drug Association (PDA) Global Conference on Pharmaceutical Microbiology from 15-16 October, in Bethesda, MD (USA). At Booth #308 Lonza experts will demonstrate how the company’s instruments, reagents and software are integrated into... Read more